Mineralys Therapeutics Inc — Cash Flow (NASDAQ:MLYS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -81.17 M-166.31 M-142.42 M -142.42 M Cash from investing activities -160.47 M114.96 M-389.75 M -389.75 M Cash from financing activities 203.25 M116.14 M591 M 591 M Free cash flow -81.17 M-166.41 M-142.43 M -142.43 M

News

Jefferies cuts Mineralys Therapeutics price target on drug concerns

Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS)

Stifel reiterates Buy rating on Mineralys stock, $52 target

BofA raises Mineralys Therapeutics stock price target on NDA progress

Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript

Mineralys earnings in focus as FDA lorundrostat decision looms

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug

Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data

H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance

Rodman sells Mineralys Therapeutics (MLYS) stock for $11,505

Mineralys Therapeutics MLYS officer sells $569k in stock

Rodman sells Mineralys (MLYS) shares for $13,353